A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients

被引：9

作者：

Kida, Daihei ^{[1
]}

Takahashi, Nobunori ^{[2
]}

Kaneko, Atsushi ^{[1
]}

Hirano, Yuji ^{[3
]}

Fujibayashi, Takayoshi ^{[4
]}

Kanayama, Yasuhide ^{[5
]}

Hanabayashi, Masahiro ^{[6
]}

Yabe, Yuichiro ^{[7
]}

Takagi, Hideki ^{[8
]}

Oguchi, Takeshi ^{[9
]}

Kato, Takefumi ^{[10
]}

Funahashi, Koji ^{[11
]}

Matsumoto, Takuya ^{[12
]}

Ando, Masahiko ^{[13
]}

Kuwatsuka, Yachiyo ^{[13
]}

Tanaka, Eiichi ^{[14
]}

Yasuoka, Hidekata ^{[15
]}

Kaneko, Yuko ^{[16
]}

Hirata, Shintaro ^{[17
]}

Murakami, Kosaku ^{[18
]}

Sobue, Yasumori ^{[2
]}

Nishiume, Tsuyoshi ^{[2
]}

Suzuki, Mochihito ^{[2
]}

Yokota, Yutaka ^{[2
]}

Terabe, Kenya ^{[2
]}

Asai, Shuji ^{[2
]}

Ishiguro, Naoki ^{[2
]}

Kojima, Toshihisa ^{[2
]}

机构：

[1] Nagoya Med Ctr, Dept Orthoped Surg & Rheumatol, Naka Ku, 4-1-1 Sanno Maru, Nagoya, Aichi, Japan

[2] Nagoya Univ, Nagoya Univ Hosp, Dept Orthoped Surg & Rheumatol, Grad Sch Med,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan

[3] Toyohashi Municipal Hosp, Dept Rheumatol, 50 Hakken Nishi,Aotake Cho, Toyohashi, Aichi, Japan

[4] Konan Kosei Hosp, Dept Orthoped Surg, 137 Oomatsubara, Konan, Aichi, Japan

[5] Toyota Kosei Hosp, Dept Orthoped Surg, 500-1 Ibohara,Josui Cho, Toyota, Aichi, Japan

[6] Ichinomiya Municipal Hosp, Dept Orthoped Surg, 2-2-22 Bunkyo, Ichinomiya, Aichi, Japan

[7] Tokyo Shinjuku Med Ctr, Dept Rheumatol, Shinjuku Ku, 5-1 Tsukudo Cho, Tokyo, Japan

[8] Nagoya Cent Hosp, Dept Orthoped Surg, Nakamura Ku, 3-7-7 Taiko, Nagoya, Aichi, Japan

[9] Anjo Kosei Hosp, Dept Orthoped Surg, 28 Higashihirokute, Anjo, Aichi, Japan

[10] Kato Orthoped Clin, 8-4 Minami Myoudaiji Cho, Okazaki, Aichi, Japan

[11] Kariya Toyota Gen Hosp, Dept Orthoped Surg, 5-15 Sumiyoshi Cho, Kariya, Aichi, Japan

[12] Shizuoka Kosei Hosp, Dept Orthoped Surg, Aoi Ku, 23 Kitaban Cho, Shizuoka, Japan

[13] Nagoya Univ Hosp, Dept Adv Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan

[14] Tokyo Womens Med Univ, Sch Med, Dept Rheumatol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo, Japan

[15] Fujita Hlth Univ, Dept Internal Med, Div Rheumatol, Sch Med, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi, Japan

[16] Keio Univ Hosp, Dept Internal Med, Shinjuku Ku, 35 Shinanomachi, Tokyo, Japan

[17] Hiroshima Univ Hosp, Dept Clin Immunol & Rheumatol, Minami Ku, 1-2-3 Kasumi, Hiroshima, Japan

[18] Kyoto Univ, Dept Rheumatol & Clin Immunol, Grad Sch Med, Sakyo Ku, 54 Kawaharacho, Kyoto, Japan

来源：

SCIENTIFIC REPORTS | 2020年 / 10卷 / 01期

关键词：

HEALTH-ASSESSMENT QUESTIONNAIRE; CONCOMITANT METHOTREXATE; SUBCUTANEOUS ABATACEPT; INADEQUATE RESPONSE; EFFICACY; SAFETY; PROGRESSION; POSITIVITY; ADALIMUMAB; REGISTRY;

D O I：

10.1038/s41598-020-76842-4

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

This study aimed to evaluate the effectiveness of abatacept (ABA) by anti-cyclic citrullinated peptide (ACPA) status on disease activity as well as radiographic progression in patients with rheumatoid arthritis (RA) in clinical settings. A retrospective cohort study was conducted using data from a multicenter registry. Data from a total of 553 consecutive RA patients treated with intravenous ABA were included. We primarily compared the status of disease activity (SDAI) and radiographic progression (van der Heijde modified total Sharp score: mTSS) between the ACPA-negative (N=107) and ACPA-positive (N=446) groups. 'ACPA positive' was defined as >= 13.5 U/mL of anti-CCP antibody. Baseline characteristics between groups were similar. The proportion of patients who achieved low disease activity (LDA; SDAI <= 11) at 52 weeks was significantly higher in the ACPA-positive group. Multivariate logistic regression analysis identified ACPA positivity as an independent predictor for achievement of LDA at 52 weeks. Drug retention rate at 52 weeks estimated by the Kaplan-Meier curve was significantly higher in the ACPA-positive group. Achievement rate of structural remission (Delta mTSS <= 0.5) at 52 weeks was similar between groups. ABA treatment demonstrated a significantly higher clinical response and higher drug retention rate in ACPA-positive patients. Progression of joint destruction was similar between the ACPA-negative and ACPA-positive groups. Close attention should be paid to joint destruction even in patients showing a favorable response to ABA, especially when the ACPA status is positive.

引用

页数：9

共 50 条

[31] Rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies with hepatitis B and hepatitis C infection: Review
Zengin, Orhan
Yildiz, Hamit
Demir, Zeynep Hanim
Dag, Muhammed Sait
Aydinli, Musa
Onat, Ahmet Mesut
Kisacik, Bunyamin
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 26 (06): : 987 - 990
[32] Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients
Mennini, Francesco Saverio
Marcellusi, Andrea
Gitto, Lara
Iannone, Florenzo
CLINICAL DRUG INVESTIGATION, 2017, 37 (04) : 375 - 386
[33] The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis
Hiura, Kazuya
Iwaki-Egawa, Sachiko
Kawashima, Toshiyuki
Fujisawa, Shin-ichi
Takeda, Tsuyoshi
Komori, Hitoshi
Watanabe, Yasuhiro
RHEUMATOLOGY INTERNATIONAL, 2013, 33 (09) : 2309 - 2314
[34] Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
Potter, C.
Hyrich, K. L.
Tracey, A.
Lunt, M.
Plant, D.
Symmons, D. P. M.
Thomson, W.
Worthington, J.
Emery, P.
Morgan, A. W.
Wilson, A. G.
Isaacs, J.
Barton, A.
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (01) : 69 - 74
[35] Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study
Kubo, Satoshi
Saito, Kazuyoshi
Hirata, Shintaro
Fukuyo, Shunsuke
Yamaoka, Kunihiro
Sawamukai, Norifumi
Nawata, Masao
Iwata, Shigeru
Mizuno, Yasushi
Tanaka, Yoshiya
MODERN RHEUMATOLOGY, 2014, 24 (01) : 42 - 51
[36] Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA
Harrold, Leslie R.
Bryson, Joshua
Lehman, Thomas
Zhuo, Joe
Gao, Sheng
Han, Xue
Schrader, Amy
Rebello, Sabrina
Pappas, Dimitrios A.
Sommers, Tanya
Kremer, Joel M.
RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 937 - 953
[37] Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis
Alemao, Evo
Johal, Sukhvinder
Al, Maiwenn J.
Rutten-van Molken, Maureen
VALUE IN HEALTH, 2018, 21 (02) : 193 - 202
[38] Clinical effectiveness and safety of additional administration of tacrolimus in rheumatoid arthritis patients with an inadequate response to abatacept: A retrospective cohort study
Suzuki, Mochihito
Takahashi, Nobunori
Kida, Daihei
Hirano, Yuji
Kato, Takefumi
Yabe, Yuichiro
Oguchi, Takeshi
Fujibayashi, Takayoshi
Hayashi, Masatoshi
Asai, Shuji
Ishiguro, Naoki
Kojima, Toshihisa
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (12) : 2199 - 2205
[39] Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial
Sokolove, Jeremy
Schiff, Michael
Fleischmann, Roy
Weinblatt, Michael E.
Connolly, Sean E.
Johnsen, Alyssa
Zhu, Jin
Maldonado, Michael A.
Patel, Salil
Robinson, William H.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (04) : 709 - 714
[40] The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study
Murata, Koichi
Hashimoto, Motomu
Yamamoto, Wataru
Son, Yonsu
Amuro, Hideki
Nagai, Koji
Takeuchi, Tohru
Katayama, Masaki
Maeda, Yuichi
Ebina, Kosuke
Hara, Ryota
Jinno, Sadao
Onishi, Akira
Murakami, Kosaku
Tanaka, Masao
Ito, Hiromu
Mimori, Tsuneyo
Matsuda, Shuichi
RHEUMATOLOGY INTERNATIONAL, 2020, 40 (02) : 217 - 225

← 1 2 3 4 5 →